Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Poor outcome after liver transplantation for transthyretin amyloid neuropathy in a family with an Ala36Pro transthyretin mutation: Case report|
|Citation:||Liver Transplantation, 2010; 16(4):470-473|
|Publisher:||W B Saunders Co|
|Department:||Medicine Learning and Teaching Unit|
|Kate R. Muller, Robert Padbury, Gary P. Jeffrey, Nicola K. Poplawski, Philip Thompson, Anne Tonkin and Hugh A. J. Harley|
|Abstract:||Transthyretin amyloid polyneuropathy, caused by mutations in the transthyretin gene, is a progressive condition for which liver transplantation is an established treatment. Favorable outcomes have been described in patients with the most common transthyretin mutation, Val30Met, but outcomes have been variable in patients with other mutations. We describe the cases of 2 siblings with transthyretin amyloid polyneuropathy secondary to an infrequently reported transthyretin mutation (Ala36Pro) who underwent liver transplantation with poor outcomes.|
|Keywords:||Humans; Amyloid Neuropathies, Familial; Alanine; Proline; Prealbumin; Treatment Outcome; Liver Transplantation; Fatal Outcome; Genotype; Mutation; Adult; Family Health; Female; Male|
|Rights:||Copyright © 2010 American Association for the Study of Liver Diseases|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.